

Curriculum Vitae

Kuan-Pin Su, M.D., Ph.D.

E-mail: cobolsu@gmail.com

Current Position	<ul style="list-style-type: none">● Professor (2012/11-) & Vice Dean (2017/08-), College of Medicine, China Medical University (CMU)● Director, Mind-Body Interface Research Centre, China Medical University Hospital (2006/08-)● Chief, Department of General Psychiatry, China Medical University Hospital (2002/3-)● Honorary Professor of Institute of Psychiatry-King's College London (2008/11-)
Professional Experience	<ul style="list-style-type: none">● 2014/08-2017/08, Chairman, Graduate Institute of Neural and Cognitive Sciences, China Medical University (CMU)● 1999/5-2002/3, Attending physician, Department of Psychiatry, Wan Fang Medical Centre & Taipei Medical University Hospital
Education & Training	<ul style="list-style-type: none">● 1988-1995, M.D., Kaohsiung Medical College, Kaohsiung, Taiwan● 1995-1999, Chief Resident and Resident, Taipei City Psychiatric Centre● 2005-2008, PhD, Institute of Psychiatry, King's College London, UK
Awards	<ul style="list-style-type: none">● 2016, The International Society for the Study of Fatty Acids and Lipids (ISSFAL): Early Career Award● 2013, Psychopharmacology Award from the British Association for Psychopharmacology (UK)● 2013, GlaxoSmithKline Depression and Anxiety Research Award, Taiwanese Society of Psychiatry, Taiwan● 2013, Professor Wen-Ho Chang Research Award, Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, Taiwan● 2012, Pacific Rim College of Psychiatrists: Young Psychiatrists Award● 2012 and 2014, The International Society for the Study of Fatty Acids and Lipids (ISSFAL): New Investigator Award● 2012, Teaching Excellency Award, China Medical University Hospital● 2012, Psychiatric Research Society Annual Meeting Travel Award (USA)● 2011, Thomson Reuters Research Front Award● 2011, GlaxoSmithKline Depression and Anxiety Research Award, Taiwanese Society of Psychiatry, Taiwan● 2011, Initiative Research Cooperation among Top Universities between UK and Taiwan, National Science Council, Taiwan● 2011, Scientific Physician, China Medical University Hospital (CMUH)● 2010, Ta-You Wu Memorial Award, National Science Council, Taiwan

- 2010, the Elite Physician of the Year, CMUH
- 2009 and 2004, the Best Physician of the Year, CMUH
- 2008, Professor Wen-Ho Chang Research Award, Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology, Taiwan
- 2008, Professor Robert Kerwin International Award from the British Association for Psychopharmacology (UK)
- 2008-2010, National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award (USA)
- 2007-2008, China Medical University Elite Faculty Scholarships
- 2007, Travel Award of the 20th ECNP
- 2006-2007, China Medical University Hospital Elite Scholarships
- 2006, Professor Janssen's Schizophrenia Research Award, Society of Psychiatry, Taiwan; Guided Tour Poster Nomination of the 19th European College Neuropsychopharmacology (ECNP); Travel Awards from King's College London; Travel Awards from Taipei Representative Office in the U.K.
- 2005-2006, Elite Program of Taiwan Merit Scholarships (TMS), Ministry of Education, Taiwan

Research Grants

Primary Investigator

- Biological mechanisms and clinical subtyping for comorbidity of chronic pain and depression: The molecular approach of central sensitization. (2017-2020, MOST106-2314-B-039-027-MY3)
- N-3 fatty acids as the first-line antidepressant therapy: From biomarkers to clinical subtypes (2016-2018, 3-Year Innovative Research Grant (IRG) of Integrated Research Grants in Health and Medical Sciences from National Health Research Institutes NHRI-EX105-10528NI)
- Pharmacogenomic approach to inflammation theory of depression: Genome-wide associations of interferon- α -induced depression (2015-2017, 2 Years, MOST104-2314-B-039-022-MY2)
- Subtyping in depression with inflammation and pain: The mechanisms underlying major depressive disorder with painful symptoms (2015-2016, China Medical University, CMU104-S-16-03)
- Effects of a melatonin receptor agonist on clinical manifestations and peripheral biological markers of circadian rhythm (2015-2016, China Medical University, CMU104-S-44)
- Pharmacogenomics of n-3 polyunsaturated fatty acids treatment for major depressive disorder: Genome-wide associations. (2014-2017, Ministry of Science and Technology MOST 103-2320-B-039-039- MY3)
- Major depression and omega-3 fatty acids: From cellular mechanisms to clinical implications (2014-2016, NSC-NCBR [National Centre for

- Research and Development, Poland] Joint Research Projects. NSC 102-2923-B-039 -002 -MY3)
- Omega-3 fatty acid on preventing depression in pregnant women (2013-2015, NSC-RS [Royal Society] Joint Research Projects 102-2911-I-039-501)
 - Phospholipid hypothesis of depression: From molecular biology, neuroimaging to behaviour (2012-2015, Project for Excellent Junior Research Investigators NSC101-2628-B-039-001-MY3)
 - The antidepressant effects for omega-3 fatty acids in cellular inflammation mechanisms (2014-2015, China Medical University CMU103-S-03)
 - Neuropsychobiology of Brain Theta-burst Stimulation: A Mind-body Interface for Depression (2012-2014, Innovative Research Grant (IRG) of Integrated Research Grants in Health and Medical Sciences from National Health Research Institutes NHRI-EX101-10144NI)
 - The protective effect of astrocyte condition medium for glutamate-induced excitotoxicity in cortical neuron (2013-2014, China Medical University Hospital DMR-103-078)
 - Genetic markers for interferon-alpha-induced depression in patients with chronic hepatitis C viral infection (2012-2013, China Medical University Hospital DMR-102-068)
 - Heterogeneity of depression: The role of genetic variations in subtyping major depressive disorder (2011-2012, China Medical University Hospital DMR-101-081)
 - Neurocognitive and neurobiological mechanisms of interferon-induced depression (2009-2012, Integrated Research Project NSC 98-2627-B-039-003)
 - N-3 polyunsaturated fatty acids in the prevention and treatment for IFN-induced depression (2009-2012, NSC 98-2628-B-039-020-MY3)
 - The biological mechanism of n-3 polyunsaturated fatty acids in depression. Initiative Research Cooperation among Top Universities between UK and Taiwan (2010-2011, NSC 99-2911-I-039-002)
 - The biological mechanism of somatic symptoms in depression: The role of polyunsaturated fatty acids. National Alliance for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award 2008-2010
 - Polyunsaturated fatty acids as biomarkers in classifying subtypes of depression (2008-2010, National Science and Technology Program for Biotechnology and Pharmaceuticals (NSTPBP) Translational Medicine Project, 97(2)-TRA-001)
 - Peripheral gene expression of PLA2 and COX2 in IFN-alpha-induced depression (China Medical University Hospital 2009-2010, DMR99-114)

- The role of neurocognitive and neurobiological markers in interferon-induced depression: an exploratory study (China Medical University 2009-2010, CMU97-336)
- The role of polyunsaturated fatty acids on sickness behaviour and depression induced by interferon therapy in patients with hepatitis C viral infection (2006-2009, NSC 95-2320-B-039-037-MY3)
- Proteomic analysis in interferon-induced sickness behavior and depression in patients with hepatitis C viral infection (CMU95-143)
- The effect of fish oil in bipolar disorder: a double-blind placebo-controlled trail for the antidepressant and maintenance effects of in bipolar disorder (2006-2008, DOH 95F022)
- Effect of fish oil diet on rat's forced-swimming test (2005-2006, NSC 94-2314-B-039-027)
- The effect of fish oil in major depressive disorder: a double-blind placebo-controlled monotherapy trail to demonstrate the therapeutic and preventive effects of depression (2005-2008, DOH 94F044)
- Omega-3 polyunsaturated fatty acids in women with major depressive disorders during pregnancy and afterbirth: from the perspectives of epidemiology, membrane psychopathophysiology, dietary differences and the double-blind placebo-controlled therapeutic trail (2002-2005, NSC 91-2320-B-039-017, 92-2320-B-039-003, 93-2320-B-039-001)
- Omega 3 fatty acids in schizophrenic disorder: from the perspectives of the double-blind placebo-controlled therapeutic trail, membrane psychopathophysiology, and dietary differences (2001-2004, NSC 90-2320-B-038-046, 91-2320-B-039-010, 92-2320-B-039-002)
- Omega 3 fatty acids in major depressive disorder: the composition of Omega 3 PUFAs in red cell membrane & parallel-group, double blind, placebo-controlled therapeutic trail (2000, NSC 89-2320-B-038-046)
- Omega 3 fatty acids in major depressive disorder: parallel-group, double blind, placebo-controlled trail (1999, Taipei Medical College, TMC88-Y05-A121)
- Lipid, glucose and leptin abnormalities induced by novel antipsychotic drugs (2003-2004, China Medical University Hospital, DMR-92-017)
- Effect of omega-3 fatty acid diet on rat's depressive-like behaviors in forced-swimming test (2004-2005, China Medical University, CMU93-M-24)
- Effect of omega-3 fatty acid diet on rat's reserpine-induced depressive-like behaviours (2005-2006, China Medical University, CMU94-105)

Co-Investigator

- Melatonergic agonists and omega-3 fatty acids in circadian rhythm and

- neuroprotection: from cellular, animal, to clinical research.
(MOS106-2314-B-038-049)
- Taiwan Clinical Trial Consortium for Mental Disorders
(MOST106-2321-B-039-004)
 - Impacts of bariatric surgeries on eating behaviors, depression, inflammation, and gut microbiomes: From animal models to evidence based medicine (MOST 106-2314-B-039-031)
 - Omega-3 fatty acids in depression of post-acute coronary syndrome patients: A double-blind placebo-controlled trial
(MOST106-2314-B-039-035)
 - Comparisons of Health Service Utilization, Medical Costs, and Risks of Medication Noncompliance and Suicidal Behavior among Patients with Depressive Disorders Using Different Antidepressants
(MOST106-2410-H-038-018)
 - Omega-3 polyunsaturated fatty acids on major depressive disorder in patients with cardiovascular diseases: a double-blind placebo-controlled therapeutic trial (3 Years, MOST104-2314-B-039-050-MY3)
 - Exploration of Anti-inflammatory and Neuroprotective Mechanisms by which Different Omega-3 Fatty Acids Treat Depression and Neurodegeneration (3 Years, MOST103-2320-B-039-041-MY3)
 - Emerging mechanisms of omega-3 fatty acids in depression: The effects of EPA and DHA on chronic stress, neurogenesis and neuroinflammation (3 Years, MOST103-2320-B-038-012-MY3)
 - A double-blind randomized controlled trial of N-3 PUFA in children with attention deficit/hyperactivity disorder (MOST103-2320-B-039-030)
 - The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO) (3 Years, JSPS 25702043 from the Japan Society for the Promotion of Science)
 - Taiwan Clinical Trial Consortium for Mental Disorders (3 years, MOST103-2325-B-039-005)
 - Production of srpk2 knockout mice and exploring the mechanisms of the pathogenesis (NSC 102-2320-B-039-039)
 - The biological mechanisms of n-3 polyunsaturated fatty acid treatment in interferon-induced depression (2 Years, NSC 101-2320-B-038-020-MY2)
 - The study of polymorphisms and expressions in genes of omega-3 fatty acid metabolism enzymes in the patients with major depressive disorder (3 Years, NSC 98-2320-B-038-018-MY3)
 - The study of effects of antidepressant treatment on leukocyte-platelet interaction in medically health patients with major depressive disorder (3 Years, NSC 98-2314-B-039-011-MY3)
 - Investigation of the effects of water extract from *Gastrodia elata* Blume on its antidepressant mechanisms in animal models and clinical study

**Committee,
Membership &
Certification**

- (CCMP95-RD-033)
- Functional MRI for depressive patients before and after received antidepressants with different mechanism (2 Years, NSC 94-2314-B-039-011, NSC 95-2314-B-039-003)
 - The study of fingerprint fluctuating asymmetry criterions on schizophrenia (NSC 92-2320-B-039-020)
 - Omega-3 fatty acids added to clozapine for patients with schizophrenia. (NSC 92-2314-B-109-003)
 - Omega-3 polyunsaturated fatty acids with the risk of Alzheimer's disease and its cognitive effects of supplementation (DOH92-TD-1095)
 - Weight gain and dyslipidemia induced by atypical antipsychotics: mechanism investigation and treatment by omega-3 fatty acids. (NSC 91-2314-B109-003)
 - The validation of the Taiwanese version of the Edinburgh Postnatal Depressive Scale (EPDS) for major depressive disorder during pregnancy and afterbirth. (China Medical University Hospital, DMR-92-92)
 - Predictors and Prevalence of Depressive Symptoms in Antenatal and Postpartum Women. (China Medical University Hospital, DMR-94-46)
 - Member of Board of Directors, the International Society for the Study of Fatty Acids and Lipids (ISSFAL) (2016-2020)
 - President of Taiwan Society for Nutritional Psychiatry Research (TSNPR) (since 2016)
 - Council Board Member of the Taiwanese Society of Biological Psychiatry and Neuropsychopharmacology (TSBPN) (since 2015)
 - President and Committee Chairman, the 1st-6th Mind-Body Interface International Symposium (Since 2010, Supported by the MOST grants)
 - Vice President, the 6th International Conference on Nutrition and Physical Activity (NAPA 2015)
 - Editorial board member of Clinical Psychopharmacology and Neuroscience (since 2014)
 - Council Board Member of the International Society for Nutritional Psychiatry Research (ISNPR) (since 2012)
 - Honorary Editor of the Journal of Traditional and Complementary Medicine (since 2013)
 - Editorial board member of the Psychiatry Investigation (since 2012)
 - International Affair Committee of the Taiwanese Society of Suicidality (since 2010)
 - Executive editor of the Taiwanese Journal of Psychiatry (since 2009)
 - Asia Consortium member of the International Society For Pharmacoeconomics and Outcomes Research (ISPOR) (since 2009)

- Membership of British Association for Psychopharmacology (2007-2010)
- Membership of European College of Neuropsychopharmacology (2007-10)
- Membership of International Society for Bipolar Disorders (2005-2010)
- Editorial Board of the Bipolar Disorders Update (2006-2008)
- Member of Organizing Committee, DEPRESSION: BRAIN CAUSES, BODY CONSEQUENCES, Royal Society of Medicine, Institute of Psychiatry, King's College London, UK (2007/4/2-3)
- Taiwanese Psychiatric Association (#000585)
- Taipei Medical Association (#16258)
- The Higher Civil Service Examination Certification (#026430)

Publication

- **See next page**
- **Reviewer for the International Journals and Funding Bodies: SEE APPENDIX**

Publications

(1) Referred Paper

1. Lin PY, Chang CH, Chong MFF, Chen H, Su KP*. Polyunsaturated fatty acids in perinatal depression: A systematic review and meta-analysis. **Biological Psychiatry** (Accepted) doi: 10.1016/j.biopsych.2017.02.1182. [Epub ahead of print]
2. Chang JPC, Su KP, Mondelli V, Pariante C. Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder (ADHD): A Systematic Review and Meta-analysis of Clinical Trials and Biological Studies. **Neuropsychopharmacology** (Accepted) doi: 10.1038/npp.2017.160. [Epub ahead of print]
3. Borsini A, Alboni S, Horowitz MA, Tojoa LM, Cannazza G, Su KP, Pariante CM, Zunszain PA. Rescue of IL-1 β -induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants. **Brain, Behavior, and Immunity** (Accepted).
4. Gałecka E, Talarowska M, Maes M, Su KP, Górski P, Kumor-Kisielewska A, Szemraj J. Expression levels of interferon- γ and type 2 deiodinase in patients diagnosed with recurrent depressive disorders **Pharmacological Reports** (Accepted).
5. Su KP*, Yang HT, Chang JP, Shih YH, Guu TW, Kumaran SS, Gałecki P, Walczewska A, Pariante CM. Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene expressions in acute depressed patients. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** (Accepted) doi: 10.1016/j.pnpbp.2017.06.020 [Epub ahead of print].
6. Chang JPC, Lin CY, Lin PY, Shih YH, Chiu TH, Ho M, Yang HT, Huang SY, Gałecki P, Su KP*. Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** (Accepted) doi: 10.1016/j.pnpbp.2017.05.008. [Epub ahead of print] (Accepted).
7. Zgórzyńska E, Dziedzic B, Gorzkiewicz A, Stulczewski D, Bielawska K, Su KP, Walczewska A. Omega-3 polyunsaturated fatty acids improve the antioxidative defense in rat astrocytes via an Nrf2-dependent mechanism. **Pharmacological Reports** (Accepted) doi: 10.1016/j.pharep.2017.04.009. [Epub ahead of print].
8. Chang JPC, Guu TW, Chen YC, Gałecki P, Walczewska A, Su KP. BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients. **Prostaglandins Leukotrienes and Essential Fatty Acids** (In Press) doi: 10.1016/j.plefa.2017.01.001. [Epub ahead of print]
9. Yang HT, Wang RY, Huang SY, Huang CL, Su KP. Genetic polymorphisms of FADS1, FADS2, and FADS3 and fatty acid profiles in subjects received methadone maintenance therapy. **Prostaglandins Leukotrienes and Essential Fatty Acids** (In Press) doi: 10.1016/j.plefa.2017.01.006. [Epub ahead of print]
10. Chang JPC, Lai HC, Yang HT, Su WP, Peng CY, Gałecki P, Walczewska A, Pariante CM, Su KP*. Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. **Nutritional Neuroscience** 2017; 20 (5), 291-296.
11. Lee CWS, Lin CL, Lin PY, Thieke S, Su KP, Kao CH. Antidepressants and risk of dementia in migraine patients: A population-based case-control study. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2017; 77: 83-89.

12. Chiu WC, Su YP, Su KP, Chen PC. Recurrence of Depressive Disorders after Interferon-induced Depression. **Translational Psychiatry** 2017 Feb; 7(2): e1026.
13. Chang JPC, Li JL, Huang YT, Lu YJ, Su KP*. Delay Aversion, Temporal Processing and N-3 Fatty Acids Intake in Children with Attention Deficit Hyperactivity Disorder (ADHD). **Clinical Psychological Science** 2016; 4(6): 1094-1103.
14. Chen YT, Su KP, Chang JP. Atypical major depressive episode as initial presentation of intracranial germinoma in a male adolescent. **Neuropsychiatric Disease and Treatment** 2016 Dec;13:35-40.
15. Nishi D, Su KP*, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Tachibana Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka Y. The synchronized trial on expectant mothers with depressive symptoms by omega-3 PUFAs (SYNCHRO): Study protocol for a randomized controlled trial. **BMC Psychiatry** 2016 Sep; 16:321 (DOI: 10.1186/s12888-016-1031-2).
16. Hsiao PJ, Hsieh PF, Chou EC, Lai HC, Peng CY, Su KP. Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C. **PLoS One** 2016 Aug 9; 11(8): e0160450.
17. Nishi D, Su KP*, Usuda K, Chiang YJ, Guu TW, Hamazaki K, Nakaya N, Sone T, Sano Y, Ito H, Isaka K, Hashimoto K, Hamazaki T, Matsuoka YJ. Omega-3 fatty acid supplementation for expectant mothers with depressive symptoms in Japan and Taiwan: An open-label trial. **Psychiatry and Clinical Neuroscience** 2016 Jun; 70(6): 253-4.
18. Senthil Kumaran S, Shih YH, Su KP*. Detecting the modest signals of omega-3 fatty acids' antidepressant effects by homogenizing depressed patient groups. **Lipid Technology** 2016 May/June; 28: 86-87.
19. Gałecka E, Talarowska M, Maes M, Su KP, Górski P, Szemraj J. Polymorphisms of iodothyronine deiodinases (DIO1, DIO3) genes are not associated with recurrent depressive disorder. **Pharmacological Reports** 2016 May; 68(5): 913-917.
20. Chang HC, Huang KC, Chiu WC, Huang KC, Tang CH, Su KP*. Changes in employment status in bipolar disorder: a longitudinal study with national claims data. **Journal of Clinical Psychiatry** 2016 Apr; 77(4): e429-35.
21. Kwiatkowski D, Czarny P, Toma M, Jurkowska N, Sliwiska A, Drzewoski J, Bachurska A, Bielecka-Kowalska A, Szemraj J, Maes M, Berk M, Su KP, Galecki P, Śliwiński T. Associations between DNA damage, DNA base excision repair genes variability and Alzheimer's disease risk. **Dementia and Geriatric Cognitive Disorders** 2016; 41(3-4): 152-71.
22. Song C, Shieh CH, Wu YS, Kalueff A, Gaikwad S, Su KP. The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer's disease: acting separately or synergistically? **Progress in Lipid Research** 2016 Jan; 62: 41-54.
23. Su KP*. Personalize medicine with omega-3 fatty acids for depression in pregnant women and children, and depression associated with inflammation. **Journal of Clinical Psychiatry** 2015; 76 (11): e1476-7.
24. Su KP*. Nutrition, psychoneuroimmunology and depression: the therapeutic implications of omega-3 fatty acids in interferon- α -induced depression. **BioMedicine** 2015; 5(4): 17-23
25. Sarris J, Nishi D, Xiang YT, Su KP, Bannatyne A, Oliver G, Heok KE, Ng C. Implementation of Psychiatric-Focused Lifestyle Medicine Programs in Asia. **Asia-Pacific Psychiatry** 2015 Dec; 7(4): 345-54.
26. Sarris J, Logan A, Akbaraly T, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka

- Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. **World Psychiatry** 2015 Oct; 14(3): 370-1.
27. Song C, Luchtman D, Kang Z, Tam EM, Yatham LN, Su KP, Lam RW. Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. **Journal of Affective Disorders** 2015 Oct 1; 185: 90-6.
 28. Su KP*, Matsuoka Y, Pae CU. Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. **Clinical Psychopharmacology and Neuroscience** 2015 Aug 31; 13(2):129-37.
 29. Czarny P, Kwiatkowski D, Gałeczki P, Talarowska M, Orzechowska A, Bobinska K, Bielecka-Kowalska A, Szemraj J, Maes M, Su KP, Sliwinski T. Association between single nucleotide polymorphisms of MUTYH, hOGG1 and NEIL1 genes, and depression. **Journal of Affective Disorders** 2015 June 3; 184: 90-96.
 30. Sarris J, Logan A, Akbaraly T, Amminger GP, Balanzá-Martínez V, Freeman MP, Hibbeln J, Matsuoka Y, Mischoulon D, Mizoue T, Nanri A, Nishi D, Ramsey D, Rucklidge JJ, Sanchez-Villegas A, Scholey A, Su KP, Jacka FN. Nutritional Medicine as Mainstream in Psychiatry. **Lancet Psychiatry** 2015 Mar; 2(3): 271-4.
 31. Chang JPC, Chang SS, Yang HT, Palani M, Chen CP, Su KP*. Polyunsaturated fatty acids levels in patients with cardiovascular diseases with and without depression. **Brain, Behavior, and Immunity** 2015 Feb; 44: 28-31.
 32. Chen WC, Lai HC, Su WP, Palani M, Su KP*. Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: An open-label study. **Psychiatry Investigation** 2015 Jan; 12(1):142-5.
 33. Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JPC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression Results from a randomized, controlled trial. **Biological Psychiatry** 2014 Oct 1; 76(7): 559-66.
 34. Talarowska M, Orzechowska A, Szemraj J, Su KP, Maes M, Gałeczki P. Manganese superoxide dismutase gene expression and cognitive functions in recurrent depressive disorders. **Neuropsychobiology** 2014 Aug; 70: 23–28.
 35. Chang JPC, Lin CC, Hwu HG, Su KP*. View on DSM from Taiwan: Transition from IV to 5. **Acta Psychiatrica Scandinavica** 2014 Mar; 129(3): 235.
 36. Talarowska M, Bobińska K, Zajączkowska M, Su KP, Maes M, Gałeczki P. Impact of oxidative/nitrosative stress and inflammation on cognitive functions in patients with recurrent depressive disorders. **Medical Science Monitor** 2014 Jan; 20: 110-5.
 37. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for major depressive disorder. **Expert Opinion On Investigational Drugs** 2013 Dec; 22(12): 1519-1534.
 38. Lu DY, Leung YM, Su KP*. Interferon- α induces nitric oxide synthase expression and heme oxygenase-1 down-regulation in microglia: Implications of cellular mechanism of IFN- α -induced depression. **International Journal of Neuropsychopharmacology** 2013 Mar; 16(2): 433-44.
 39. Tseng YL, Chiang ML, Lane HY, Su KP, Lai YC. Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation. **Thrombosis Research** 2013 Apr; 131(4): 325-32.
 40. Lin SH, Chang HC, Chen PJ, Hsieh CL, Su KP, Sheen LY. The antidepressant-like effect of ethanol

extract of daylily flowers in rats. **Journal of Traditional and Complementary Medicine** 2013 Jan; 3(1): 53-61.

41. Lin PY, Mischoulon D, Freeman MP, Matsuoka Y, Hibbeln J, Belmaker RH, Su KP*. Are omega-3 fatty acids anti-depressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. **Molecular Psychiatry** 2012 Dec; 17(12): 1161-3.
42. Lin PY, Chiu CC, Huang SY, Su KP*. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. **Journal of Clinical Psychiatry** 2012; 73(9): 1245-1254.
43. Su KP. Inflammation in psychopathology of depression: Clinical, biological, and therapeutic implications. **BioMedicine** 2012 June; 2(2): 68-74.
44. Chang HC, Tang CH, Huang ST, McCrone P, Su KP*. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror image study with national claim-based database in Taiwan. **Journal of Psychiatric Research** 2012 Jun; 46(6): 751-6.
45. Liang JA, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Kao CH. A nationwide population-based cohort study: Anxiety disorders will increase subsequent cancer risk? **PLoS ONE** 2012 April; 7(4): e36370, 1-6.
46. Kao CH, Sun LM, Su KP, Chang SN, Sung FC, Muo CH, Liang JA. Use of benzodiazepine increases cancer risk – A population-based cohort study in Taiwan. **Journal of Clinical Psychiatry** 2012 April; 73(4): 555-560.
47. Jadoona A, Chiu CC, McDermott L, Cunningham P, Frangou S, Chang CJ, Sun YW, Liu SI, Lu ML, Su KP, Huang SY, Stewart R. Associations of polyunsaturated fatty acids with residual depression or anxiety in older people with major depression. **Journal of Affective Disorders** 2012 Feb;136(3): 918-25.
48. Chen YT, Su KP, Chang J. Early detection and management of atypical Neuroleptic malignant syndrome secondary to aripiprazole. **Schizophrenia Research** 2011 Sep; 132(1): 97-98.
49. Chen PJ, Liang KC, Lin HC, Hsieh CL, Su KP, Hung MC, Sheen LY. *Gastrodia elata* Bl. Attenuated Learning Deficits Induced by Forced-Swimming Stress in the Inhibitory Avoidance Task and Morris Water Maze. **J Med Food** 2011 Jun; 14(6): 610-7.
50. Guu TW, Su KP*. Musical creativity and mood bipolarity in Robert Schumann- A tribute to the 200th anniversary of the composer's birth. **Psychiatry and Clinical Neuroscience** 2011; 65: 112-114. (*Correspondence).
51. Chang J, Wu CC, Su KP*. A case of venlafaxine-induced bruxism alleviated by duloxetine substitution. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2011; 35: 307. (*Correspondence).
52. Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. **Thrombosis Research** 2010 Dec; 126(6): 517-523.
53. Lu DY, Tsao YY, Leung YM, Su KP*. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: Implications of antidepressant effects for omega-3 fatty acids. **Neuropsychopharmacology** 2010 Oct; 35(11): 2238–2248. (*Correspondence).
54. Wu CC, Chang J, Liou JS, Su KP*. A case of milnacipran-induced sweating alleviated by duloxetine substitution. **Journal of Clinical Psychopharmacology** 2010 Oct; 30(5): 640-1. (*Correspondence).
55. Chang J, Su KP*. The lipid raft hypothesis: the relation among omega-3 fatty acids, depression and

- cardiovascular diseases. **Taiwanese Journal of Psychiatry** 2010 Sep; 24(3): 168-80. (*Correspondence).
56. Lin PY, Huang SY, Su KP*. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. **Biological Psychiatry** 2010; 68(2):140-147. (*Correspondence).
 57. Wu CC, Tsai CH, Lu MK, Chen CM, Shen WC, Su KP*. Theta-burst repetitive transcranial magnetic stimulation for treatment-resistant obsessive-compulsive disorder with concomitant depression. **Journal of Clinical Psychiatry** 2010 April; 71(4): 504-506. (*Correspondence).
 58. Su KP, Huang SY, Peng CY, Lai CH, Huang CL, Chen YC, Aitchison KJ, Pariante CM. Phospholipase A2 and cyclo-oxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. **Biological Psychiatry** 2010; 67(6): 550-557.
 59. Chang J, Wu CC, Su KP*. Paliperidone overdose in a patient with schizophrenia. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2010 Mar; 34(2): 418. (*Correspondence).
 60. Su KP*, Chang HC*, Tsai SJ, Tang CH. Relapse and long-acting injectable risperidone: A one-year mirror image study with a national claims database in Taiwan. **Value in Health** 2009; 12(S3): S118-S121.
 61. Su KP. The biological mechanism of antidepressant effect of omega-3 fatty acids: How does fish oil acts as a “mind-body interface?” **NeuroSignals** 2009 Feb; 17(2): 144-152.
 62. Chang HC, Tang CH, Tsai SJ, Yen FC, Liu JP, Su KP*. Long-acting injectable risperidone and hospital readmission: A mirror image study with a national claim-based database in Taiwan. **Journal of Clinical Psychiatry** 2009 Jan; 70(1): 141. (*Correspondence).
 63. Chen PJ, Hsieh CL, Su KP, Hou YC, Chiang HM, Sheen LY. Rhizomes of *Gastrodia elata* B(L) Possess Antidepressant-Like Effect via Monoamine Modulation in Subchronic Animal Model. **Am J Chin Med** 2009; 37(6): 1113-24.
 64. Chang J, Wu PL, Lane HY, Su KP*. Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment for Isaacs Syndrome with Depression. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2009 Jun 15; 33(4): 739-40. (*Correspondence).
 65. Chang J, Chen YT, Su KP*. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cardiovascular diseases (CVD) and depression: the missing link? **Cardiovascular Psychiatry and Neurology** 2009(2009), Article ID 725310, 6 pages. doi:10.1155/2009/725310. (*Correspondence).
 66. Wu CC, Su KP. Quetiapine-induced Rabbit Syndrome in a patient with bipolar disorder. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008 Dec; 32(8):2002-3.
 67. Chiu CC, Liu JP, Su KP*. The use of omega-3 fatty acids in treatment of depression: the lights and shadows. **Psychiatric Times** 2008 Aug; 25(9): 76-80. (*Correspondence).
 68. Su KP*, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. **Journal of Clinical Psychiatry** 2008 Apr; 69(4): 644-651. (*Correspondence).
 69. Chiu CC, Su KP, Cheng TC, Liu HC, Stewart R, Huang SY. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008; 32(6): 1538–1544.
 70. Liao CC, Huang CL, Chang YH, Lin CC, Su KP*. Red Yeast Rice for a patient with

olanzapine-induced dyslipidemia: a test-and-retest case report. **Progress in Neuro-Psychopharmacology & Biological Psychiatry** 2008 Jul; 32(5): 1340-1341. (*Correspondence).

71. Wang JF, Lin CL, Chang YH, Chen TY, Su KP, Nagurka ML. Determining the association between dermatoglyphics and schizophrenia by using fingerprint asymmetry measures. **International Journal of Pattern Recognition and Artificial Intelligence** 2008; 22(3): 601-616.
72. Chen PJ, Hsieh CL, Su KP, Hou YC, Chiang HM, Lin IH, Sheen LY. The Antidepressant Effect of *Gastrodia elata* Bl. on the Forced-Swimming Test in Rats. **American Journal of Chinese Medicine** 2008 Jan; 36(1): 95-106.
73. Su KP*. Mind-body interface: The role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression. **Asia Pacific Journal of Clinical Nutrition** 2008 Jan; 17(S1): 147-153.
74. Huang SY, Yang HT, Chiu CC, Pariante C, Su KP*. Omega-3 fatty acids on the forced-swimming test. **Journal of Psychiatric Research** 2008 Jan; 42(1): 58-63. (*Correspondence).
75. Su KP*, Chiu TH, Huang CL, Ho M, Lee CC, Wu PL, Lin CY, Liao CH, Liao CC, Chiu WC, Pariante CM. Different cut-off points for different trimesters? The use of Edinburgh Postnatal Depression Scale and Beck Depression Inventory to screen depression during pregnancy in Taiwan. **General Hospital Psychiatry** 2007 Sep-Oct; 29(5): 436-41. (*Correspondence).
76. Lin PY, Su KP*. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. **Journal of Clinical Psychiatry** 2007 Jul; 68(7): 1056-1061. (*Correspondence).
77. Wu PL, Liao KF, Peng CY, Pariante CM, Su KP*. Manic episode associated with citalopram therapy for IFN-induced depression in a patient with chronic hepatitis C infection. **General Hospital Psychiatry** 2007 Jul-Aug; 29(4): 374-6. (*Correspondence).
78. Huang CL, Su KP*, Hsu HB, Pariante C. A pilot crossover study on QTc interval associated with olanzapine and risperidone. **Journal of Clinical Psychiatry** 2007 May; 68(5): 803-5. (*Correspondence).
79. Lin CY, Wu PL, Pariante C, Su KP*. A crossover study on prolactin changes associated with risperidone and olanzapine. **Journal of Clinical Psychiatry** 2006 Sep; 67(9): 1470-1471. (*Correspondence).
80. Liao CH, Shen WW, Su KP*. Venlafaxine-associated serotonin syndrome and manic episode in a geriatric depressive patient. **Psychiatry and Clinical Neuroscience** 2006; 60(1): 121-122. (*Correspondence).
81. Wu PL, Lane HY, Su KP*. Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus. **Psychiatry and Clinical Neuroscience** 2006; 60(1): 115-116. (*Correspondence).
82. Chiu CC, Huang SY, Chen CC, Su KP*. Omega-3 fatty acids is more beneficial to depression than to mania in patients with bipolar I disorder. **Journal of Clinical Psychiatry** 2005 Dec; 66(12): 1613-14. (*Correspondence).
83. Su KP*, Wu PL, Pariante C. A crossover study on of lipid and weight changes associated with olanzapine and risperidone. **Psychopharmacology** 2005 Dec; 183(3):383-386. (*Correspondence).
84. Huang SY, Chiu CC, Shen WW, Chang HC, Su KP*. Hypoalbuminemia in drug-free patients with

- major depressive disorder compared with a dietary matched control group: A clinical meaning beyond malnutrition. **European Neuropsychopharmacology** 2005; 15(2): 227-230. (*Correspondence).
85. Chiu CC, Huang SY, Su KP*. Omega-3 polyunsaturated fatty acids for postpartum depression. **American Journal of Obstetrics and Gynecology** 2004; 190 (2): 582-583. (*Correspondence).
 86. Su KP, Chuang CL, Chen KP, Lane HY, Shen WW. Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome. **Schizophrenia Research** 2004; 66 (2-3): 191-192.
 87. Huang SY*, Wu SS, Chiu CC, Kuo CJ, Su KP, Lu ML. Assessment of Dietary Intake and Blood Fatty Acid Composition in Patients with Schizophrenia. **Nutrition Science Journal** 2004; 29(1): 21-30. [Full text in Chinese]
 88. Su KP*, Huang SY*, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. **European Neuropsychopharmacology** 2003; 13(4): 267-271. (*Correspondence).
 89. Chiu CC, Huang SY, Su KP*, Lu ML, Huang MC, Chen CC, Shen WW. Polyunsaturated fatty acid deficit in patients with bipolar mania. **European Neuropsychopharmacology** 2003; 13(2): 99-103. (*Correspondence).
 90. Chiu CC, Huang SY, Shen WW, Su KP*. Omega-3 fatty acid monotherapy for a pregnant patient with major depressive disorder. **American Journal of Psychiatry** 2003; 160(2): 385. (*Correspondence) **[Erratum on affiliation: American Journal of Psychiatry 2003; 160 (4): 801]**
 91. Su KP, Chuang CL, Chen KP, Chen CC, Shen WW. A pilot cross-over design study on QTc interval prolongation associated with sulpiride and haloperidol use. **Schizophrenia Research** 2003; 59(1): 93-34.
 92. Su KP, Leu SYC, Yang YY, Shen WW, Chou YM, Tsai SYM. The change of interferon-gamma and interleukine-10 in bipolar mania and subsequent remission. **Journal of Affective Disorders** 2002; 71: 205-9. **[Erratum on affiliation: Journal of Affective Disorders 2003; 73: 299]**
 93. Lu ML, Pan JJ, Teng HW, Su KP, Shen WW. Metoclopramide-Induced supersensitivity psychosis. **Annals of Pharmacotherapy** 2002; 36: 1387-90.
 94. Su KP, Chang HC, Shen WW. QTc Prolongation associated with haloperidol, risperidone and ziprasidone. **American Journal of Psychiatry** 2002; 159: 1062-1063.
 95. Pan CC, Shen WW, Su KP*. Individual psychotherapy for transsexualism with the co-morbidity of depressive disorder - 3 cases reports. **Taiwanese Journal of Psychiatry** 2002; 16(3): 237-242. (*Correspondence)
 96. Su KP, Huang SY, Shen WW. Brief review on lipid abnormalities induced by novel antipsychotic drugs. **Drug Safety** 2001; 24 (13): 1017-8.
 97. Su KP, Shen WW, Huang SY. Omega-3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient. **European Neuropsychopharmacology** 2001; 11(4): 295-299.
 98. Su KP, Hsu CY, Hsieh SC, Shen WW. Magnetic resonance imaging findings in patients with delusional disorder due to diffuse cerebrovascular disease: a report of seven cases. **Psychiatry and Clinical Neuroscience** 2001; 55(2): 121-126
 99. Hsieh WC, Shen WW, Pan CC, Su KP*. Intensive stress-management Group psychotherapy on outpatients with anxiety disorders: a pilot demonstration. **Taiwanese Journal of Psychiatry** 2001; 15(2): 117-125. (*Correspondence).
 100. Su KP, Yu JM, Yang TW, Tsai SY, Chen CC. Mentally retarded criminal offenders in northern Taiwan.

Journal of Forensic Science 2000; 45(6): 1207-1209

101. Su KP, Huang SY, Shen WW. Effects of polyunsaturated fatty acids on psychiatric disorders. **American Journal of Clinical Nutrition** 2000; 72(5): 1241
102. Shen WW, Su KP. Torsadogenicity and antipsychotic drugs. **Taiwanese Journal of Psychiatry** 2000; 14(3): 6-22.
103. Su KP, Huang SY, Shen WW. Is omega 3 fatty acids beneficial in depression but not mania? **Archives of General Psychiatry** 2000; 57(7): 716.
104. Su KP, Tsai SY, Huang SY. Cholesterol, depression and suicide. **British Journal of Psychiatry** 2000; 176(4): 399.
105. Su KP, Lee HC, Pan CC, Tsai SY. The screening of depressed mood in the elderly Taiwanese. **New Taipei Journal of Medicine** 2000; 2(2): 81.
106. Su KP, Lee HC, Pan CC, Huang SY. Lipid and psychiatric disorders: Does total serum cholesterol matter? **Taiwanese Journal of Psychiatry** 2000; 14(1): 77-9.
107. Su KP, Lee YJ, Lee MB. Severe peripheral polyneuropathy and rhabdomyolysis in lithium intoxication: a case report. **General Hospital Psychiatry** 1999; 21(2): 136-7.
108. Lane HY, Su KP, Chang WH. Seizures after Discontinuation of Low-Dose Lorazepam From Originally Seizure-Free Clozapine Regimen: Combined Effects? **Journal of Clinical Psychiatry** 1999; 60(6): 408-409.
109. Lane HY, Su KP, Chang WH. Elevated plasma clozapine concentrations after phenobarbital discontinuation. **Journal of Clinical Psychiatry** 1998; 59(3): 131-3.

● **SSCI/SCI: 99 (first author: 27, *Correspondence author: 46)**

● **Impact Factors>10: 10 papers**

● **Impact Factors>5: 33 papers**

(2) Book chapter

1. Su KP, Balanzá-Martínez V. Role of omega-3 fatty acids in mood disorders (Chapter 16). In McNamara RK, Editor. *The omega-3 fatty acid deficiency syndrome: opportunities for disease prevention*. Nova Science Pub Inc., NY, USA: 2013, pp. 315-336 (ISBN 978-1-62417-703-3).
2. Chang JPC, Su KP. Omega-3 polyunsaturated fatty acids (PUFAs) as the “Mind-Body Interface” in cardiovascular diseases and depression. In: Rodriguez-Cruz M, Editor. *The latest finding of the long chain polyunsaturated fatty acids: since molecular mechanism to new application in the health*. Bentham Science Publishers, Bussum, Netherlands: 2011, pp. 58-66. (ISBN 978-1-60805-356-8)
3. Su KP, Shen WW, Huang SY. The use of omega-3 fatty acids for the management of depression and psychosis during pregnancy and breast-feeding. In: Peet M, Glen I, Horrobin DF, Editors. *Phospholipid spectrum disorder in psychiatry and neurology*, 2nd ed. Marius Press, 2003, Carnforth, UK: pp. 391-399. (ISBN 978-1871622256)

(3) Conference Paper (in recent 5 years)

1. Su KP. Omega-3 fatty acids support brain, mind and body: From bench to bedside, The 26th Japanese Society of Lipid Nutrition (JSLN), Tokyo, Japan, Sep 22-23, 2017 (**Keynote Speaker**)

2. Su KP. (1) The devil is in the details: Insights from clinical studies of omega-3 fatty acids in depression (**Keynote**); (2) Personalized medicine with omega-3 fatty acids in treatment of depression associated with inflammation (Symposium: Omega-3 polyunsaturated fatty acid in prevention of depression and post-traumatic stress in person with special physical condition, **Speaker**); (3) Polyunsaturated fatty acids in perinatal depression: A systematic review and meta-analysis (Symposium: Promoting Nutritional Psychiatry Research from Taiwan, **Speaker and Chair**), The 2017 Annual Congress International Society for Nutritional Psychiatry Research (ISNPR), Marriott Hotel Bethesda, Washington DC, USA, July 30-Aug 2, 2017 (**Symposium Chair and Keynote Speaker**)
3. Su KP. Omega-3 fatty acids, inflammation and depression: From biological mechanisms to clinical application (S-08: Inflammation markers of peripheral blood in depression spectrum), The 13th World Congress of Biological Psychiatry, in Copenhagen, Denmark, June 18-22, 2017 (**Symposium Speaker**)
4. Su KP. Omega-3 fatty acids for depression. The 4th International Forum on Omega-3 and Human Health, Chongqing, China, March 2-3, 2017 (**Keynote speaker**)
5. Su KP. Omega-3 and Health Promotion & Disease Management: From Animals to Humans. Inaugural symposium of the International Society for Omega-3 Research: Boston, USA, Jan 8-9, 2017 (**Keynote speaker**)
6. Su KP. (1) "The devil is in the details: insights from clinical studies of nutritional intervention in depression" in the symposium of "Nutritional medicine as mainstream in psychiatry" and (2) "Personalized medicine with fish oils for depression" in the symposium of "Lifestyle medicine and nutraceuticals in psychiatry" @ The 17th Pacific Rim College of Psychiatrists (PRCP) Congress, Kaohsiung, Taiwan, Nov 3-5, 2016 (**Symposium Chair and Speaker**)
7. Su KP. Personalized medicine with omega-3 fatty acids for depression. The 9th International Stress and Behavior Society (ISBS) Conference, Guangdong Ocean University, Zhanjiang, China, Oct 27-29, 2016 (**Keynote speaker**)
8. Su KP. The devil is in the details: insights from clinical studies of omega-3 fatty acids in depression. ISSFAL EARLY CAREER AWARD LECTURE on 2016/9/9; Chairman of the Concurrent 23, Fatty Acids and Lipids in Aging on 2016/9/9; The 12th Biennial International Society for the Study of Fatty Acids and Lipids (ISSFAL), Stellenbosch, South Africa, September 5-9, 2016 (**Keynote speaker**)
9. Su KP. Clinical and biological aspects of personalizing omega-3 fatty acids in depression. The ISNPR International Satellite Symposium @ the 18th Annual Conference of the International Society for Bipolar Disorders (ISBD) and the 8th Biennial Conference of The International Society for Affective Disorders (ISAD), Amsterdam, Netherland, July 13-16, 2016 (**Symposium Speaker**)
10. Su KP. Personalize medicine with omega-3 fatty acids for depression. The Annual Congress of Polish Psychiatric Association, Katowice, Poland, June 16-18, 2016 (**Invited Speaker**)
11. Su KP. Personalize medicine with omega-3 fatty acids for depression, Annual International Symposium at the Chonnam National University Medical School, Gwangju, Korea, May 27-29, 2016 (**Invited Speaker**)
12. Su KP. Omega-3 fatty acids for inflammation-related depression, in the Symposium "Biological mechanisms underlying Inflammation in psychiatric disorders: classification and therapeutic applications" in the 71st Annual Congress of SOBP, on May 12-14, 2016 in Atlanta, Georgia, USA (**Symposium Speaker**)
13. Su KP. The World Psychiatry Association International Congress (WPAIC), Taipei, Taiwan, November 18-22, 2015 (**Congress Committee, Symposium Chair and Invited Speaker**)
 - (1) 2015/11/20 (Fri), 0830-1000, **Moderator** in the YIA Psychosomatics session;
 - (2) 2015/11/20 (Fri) 1500-1530, **Special Lecture 4**, Personalize Medicine with Omega-3 Fatty Acids for Depression, WPAIC Special Lecture;
 - (3) 2015/11/21 (Sat) 1600-1730, **Invited Speaker**, Experimental Frontiers in Treatment for Depression, WPAIC AsCNP Symposium
14. Su KP. Personalize medicine with omega-3 fatty acids for depression, @ the International Conference on Nutrition and Physical Activity (NAPA): Healthy Lifestyle to Improve Quality of Life, Prof Sheen, Taipei, Taiwan, October 21-24, 2015 (**Conference Vice President, Symposium Chair and Speaker**)

15. Su KP. (1) Opening remarks; (2) Moderator for Tom Brenna; (3) Moderator for Felice Jacka, The 5th MBI International Symposium, Taichung, Taiwan, October 20-21, 2015 (**Symposium Committee Chair and Speaker**)
16. Su KP. Personalize medicine with omega-3 fatty acids for depression, Organized by Dr Mizoue for the 62nd Annual Meeting of the Japanese Society of Nutrition and Dietetics, Fukuoka, Japan, September 24-26, 2015 (**Keynote speaker**)
17. Su KP*. "Omega-3 PUFAs in major depressive disorder in pregnant women" from the symposium titled "Challenge of nutritional psychiatry to depression in pregnant women", The 23rd World Congress of Psychosomatic Medicine (WCPM: <http://www.icpm2015.com>), Glasgow, UK August 19-22, 2015 (Invited Speaker)
18. Su KP*. Mind-Body Interface: From Bedside to Bench for Omega-3 Fatty Acids in Depression, Polish Institute of Neurobiology (Nencki Institute of Polish Academy of Sciences), Warsaw, Poland, July 28, 2015 (**Invited Speaker**)
19. Su KP*. Personalize medicine with omega-3 fatty acids for depression, The 70th Annual Scientific Convention of Society of Biological Psychiatry, Toronto, Ontario, Canada, May 14-16, 2015 (**Symposium Chair and Speaker**)
20. Su KP*. How Omega-3 Fatty Acids Interface Mind and Body, The XVI World Congress of Psychiatry, Madrid, Spain, 14th – 18th September, 2014 (**Invited Speaker**)
21. Su KP*. N3 in prevention of IFN-induced depression, The 11th Biennial ISSFAL, Stockholm, Sweden, 28th June – 2nd July, 2014 (**New Investigator Award**, Invited Speaker)
22. Su KP*. Omega-3 fatty acids in treatment and prevention of major depression, The 2nd ISNPR Meeting, Deakin City Centre, Melbourne, Australia, 3rd-4th, April, 2014 (Invited Plenary Speaker)
23. Su KP*. Health service utilization and long-acting injectable antipsychotic treatment: results from the national claim-based database in Taiwan. Symposium of Phase Specific Treatment of Schizophrenia with Christoph, Taishiro & Kane. The 3rd Asian College of Neuropsychopharmacology (AsCNP), Beijing, China, 11th-14th, September, 2013 (Invited Speaker)
24. Su KP*. Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications. The Annual Meeting of British Association for Psychopharmacology (BAP), Harrogate, UK, 28 - 21 July, 2013. (**BAP Psychopharmacology Award**, Invited Speaker)
25. Su KP*. Mind-Body Interface: Omega-3 fatty acids in the prevention of interferon-alpha-induced depression, The 11th World Congress of Biological Psychiatry, in Kyoto, Japan, 23 - 27 June 2013 (Invited Speaker)
26. Su KP* & Yutaka Matsuoka. Overview of Nutritional Psychiatry. The 1st International Society of Nutritional Psychiatry Research (ISNPR), at the National Institute of Health and Nutrition in Tokyo, Japan, 21st June, 2013 (Symposium Chairs)
27. Su KP*. Omega-3 in depression: the biological, therapeutic and preventive implications, The 1st International Society of Nutritional Psychiatry Research (ISNPR), at the National Institute of Health and Nutrition, Tokyo, Japan, 21st June, 2013 (Invited Speaker)
28. Su KP*. Omega-3 fatty acids in depression: The biological, therapeutic and preventive implications. The Global Omega-3 Summit 2013, Crowne Plaza Le Palace, Brussels, Belgium, 30th May, 2013 (Invited keynote speaker).
29. Su KP*. Omega-3 fatty acids in the prevention of interferon-induced depression. The CINP Thematic Meeting on Personalised Medicine, Jerusalem, Israel, 21-23, April, 2013 (Invited Speaker)